June 3rd

Striker Oil & Gas Announces 137 Gross Barrels Per Day Recompletion in Its North Edna Prospect

Striker Oil & Gas, Inc. (OTCBB: SOIS) announced today that it has successfully recompleted the LeJeune No. 1 well in its North Edna prospect located in Jefferson Davis Parish, Louisiana. The well came online last week and is currently producing 137 gross barrels of oil per day to the 100% working interest. The decision to move uphole to perforate what could be the best zone in the well was made necessary when the last zone ceased to flow. Based on the current flowing oil rate of the well, payout of the recompletion should occur in less than 15 days. Using current prices and the evaluation of this zone by Striker\'s third party reservoir engineering firm, approximately $1,000,000 in net revenue should be generated to Striker\'s interest from this single interval. The North Edna Field has produced over 10 Bcf of gas and 700,000 barrels of oil. Striker has a 40% working interest before payout and a 29.6% net revenue interest before payout in this prospect.
Published: 03 June 2008
Written by Editor
Read more: Striker Oil & Gas Inc ( SOIS )

June 3rd

Protalix BioTherapeutics to Initiate an Open-Label Extension Study for the Phase III Clinical Trial of prGCD

Protalix BioTherapeutics, Inc. (Amex: PLX), today announced that it intends to initiate a double-blind, follow-on extension study as part of the Company’s on-going phase III clinical trial of its lead product candidate, prGCD, a proprietary plant cell expressed recombinant form of human Glucocerebrosidase (GCD) for the treatment of Gaucher disease, a lysosomal storage disorder in humans.

Eligible patients who have successfully completed treatment as part of the pivotal phase III clinical trial will be offered the opportunity to continue to be treated with prGCD at the same dose that they received in the trial. The objective of the proposed extension study is to compile additional information relating to the long term safety and efficacy of prGCD.
Published: 03 June 2008
Written by Editor
Read more: Protalix BioTherapeutics Inc ( PLX )

June 3rd

Lexicon\'s Drug Candidate for Carcinoid Syndrome Receives Fast Track Status From the FDA

LX1032 Multi-Dose Trial to be Initiated in June

Lexicon Pharmaceuticals, Inc. (Nasdaq:LXRX), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, announced today that it has received Fast Track status from the U.S. Food and Drug Administration (FDA) for development of LX1032, an orally-delivered small molecule drug candidate for managing gastrointestinal symptoms associated with carcinoid syndrome. LX1032 is one of four programs in human clinical trials as part of Lexicon\'s 10TO10 program.

\"Fast Track status can accelerate the development and expedite the review of LX1032,\" said Arthur T. Sands, M.D., Ph.D., president and chief executive officer at Lexicon. \"The FDA recognizes the serious unmet medical need of patients with carcinoid syndrome who no longer respond to standard care and the potential benefits that LX1032 could have for those suffering from this disease.\"
Published: 03 June 2008
Written by Editor
Read more: Lexicon Pharmaceuticals Inc ( LXRX )

June 3rd

VNUS Announces Settlement of Patent Litigation with AngioDynamics and Vascular Solutions

VNUS(R) Medical Technologies, Inc. (Nasdaq: VNUS) today announced that it has entered into an Agreement with AngioDynamics (Nasdaq: ANGO) and Vascular Solutions (Nasdaq: VASC) that settles and resolves the patent infringement lawsuit between the companies filed in 2005. The Agreement results in VNUS granting to AngioDynamics and Vascular Solutions, a non-exclusive, non-sublicensable patent license that covers certain products such as disposable endovenous laser fiber kits, laser fibers, and lasers used in the field of endovenous laser ablation.

As a part of the agreement, licensees AngioDynamics and Vascular Solutions stipulated that the VNUS patents-in-suit are valid, enforceable, and were infringed by the licensees.
Published: 03 June 2008
Written by Editor
Read more: VNUS(R) Medical Technologies Inc ( VNUS )

June 3rd

Zix Corporation Continues Industry Leadership With Record Breaking 11 Million ZixDirectory(TM) Members

Zix Corporation (ZixCorp(R)), (Nasdaq: ZIXI), the leader in hosted services for email encryption and e-prescribing, today announced that its ZixDirectory marked another industry first by reaching 11 million email encryption members. ZixDirectory is the largest email encryption directory in the world, interconnecting a network of communities that use ZixCorp\'s Email Encryption Service to send and receive secure email.

ZixDirectory connects all ZixCorp customers for seamless, transparent, and secure email. The ZixDirectory has now grown to include more than 1,000 hospitals, 30 Blues organizations, more than 600 financial institutions, the federal banking regulators,
Published: 03 June 2008
Written by Editor
Read more: Zix Corporation ( ZIXI )
  1. NetQoS Introduces Trade Monitor for FIX Financial Protocol Monitoring
  2. The ‘service enabler’ role holds the greatest revenue potential
  3. ASC to Exhibit Sophisticated Quality Monitoring and VoIP Recording Solutions
  4. Cline Mining Corporation ( CMK )
  5. Intrepid Technology and Resources Inc ( ITRP )